Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laruparetigene Zovaparvovec in Male Participants With X-Linked Retinitis Pigmentosa
NCT07174726Phase 2Active, not recruiting
- Sponsor
- Beacon Therapeutics
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of laruparetigene zovaparvovec in X-linked retinitis pigmentosa (XLRP), sponsored by Beacon Therapeutics. Started Sep 2025; status: active, not recruiting.
02
Drugs
laruparetigene zovaparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on NCT07174726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174726.